• Fluvoxamine improved fatigue: Significant reductions in Fatigue Severity Scale scores at day 60 (−0.43) and day 90 (−0.58) vs placebo, with high probability of superiority.
• No benefit with metformin: No significant or sustained improvement in fatigue or recovery endpoints compared with placebo.
• Quality of life gains: Fluvoxamine improved EQ-5D-5L scores across all time points, aligning with fatigue improvements.
• Higher recovery rates: Patients receiving fluvoxamine were more likely to achieve FSS <3 at days 30, 60, and 90.
• Well tolerated: Adverse events were less frequent with fluvoxamine (20%) vs metformin (28.8%) and placebo (29.7%), with few serious events

Source: Annals of Internal Medicine